AUTHORS
Jingwei Yu, MD, Lanfang Li2, Zhengzi Qian3, Wei Li4, Zhao Peiqi, MD5, Xianming Liu6, Linli Pan7, Zhigang Guo, PhD.8, Jiannna Chen, PhD.9, Yaoyao Zhao, PhD.10, Zhengliang Chen, PhD.11, Zongwei He, PhD.12, Jun Yu, MD, PhD,13, Huilai Zhang, PhD14, Jihui Hao, MD, PhD,15
AFFILIATIONS
1 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
2 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
3 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
4 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
5 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
6 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
7 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
8 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
9 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
10 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
11 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
12 Nanjing Miracle Biotechnology Co., Ltd, Nanjing, China
13 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
14 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
15 Tianjin Medical University Cancer Institute &Hospital, Tianjin, China
ABSTRACT
Background
CD70 is broadly expressed in hematologic malignancies with limited expression in normal tissues, making it an attractive target for CAR-T therapy. CHT101 is an allogeneic CD70-targeted CAR-T cell product designed as an off-the-shelf therapy for participants with relapsed/refractory (R/R) hematologic malignancies. Here, we report preliminary safety, pharmacokinetic (PK), pharmacodynamic (PD), antitumor activity, and exploratory biomarker analyses from the ongoing Phase 1 COURAGE study (NCT06914037).
Methods
This single-center, open-label, phase I study evaluated CHT101 in participants with R/R hematologic malignancies using accelerated titration followed by a 3+3 dose-escalation design. Following lymphodepletion with cyclophosphamide and fludarabine, participants received CHT101 as equal fractionated infusions on Days 1–3, with daily dose levels of 6.0×108, 9.0×108, or 12.0×108 CAR+ T cells. Primary endpoints included safety, dose-limiting toxicities (DLTs), and determination of RP2D or biological effective dose. Secondary endpoints included PK, PD, and antitumor activity. Exploratory analyses evaluated CD70 expression by immunohistochemistry (IHC) and DIA-based liquid chromatography-tandem mass spectrometry (DIA-LC–MS/MS) in available FFPE tumor samples.
Results
As of July 18, 2026, 14 participants were screened and 7 enrolled: 4 with classical Hodgkin lymphoma (cHL), 1 with peripheral T-cell lymphoma (PTCL), 1 with cutaneous T-cell lymphoma (CTCL), and 1 with angioimmunoblastic T-cell lymphoma (AITL). One cHL participant discontinued lymphodepletion due to thyroid dysfunction and deferred CHT101 infusion. Six participants received CHT101 and were evaluable for safety and efficacy. Median age was 62 years (range, 26–68), with a median of 3 prior treatment lines (range, 1–4). Six of 7 enrolled participants (85.7%) were CD70 positive.
No DLTs were observed. No CHT101 infusion interruptions, treatment discontinuations, treatment-related SAEs, or deaths occurred. Grade ≥3 TEAEs were reported in 6 participants (85.7%), all of which were considered related to CHT101, predominantly hematologic abnormalities and largely attributable to prior antitumor therapies and/or lymphodepleting chemotherapy. CRS occurred in 2 participants (28.6%; Grade 2/3), both resolved with tocilizumab and supportive care. GVHD occurred in 3 participants (42.9%; Grade 1–2), all resolved with corticosteroids and supportive care.
With a median follow-up of 3.24 months (range, 1.8–12.0), best overall responses included CR (n=1), PR (n=2), and SD (n=2). ORR was 50.0% (95% CI, 11.8%–88.2%), and DCR was 83.3% (95% CI, 35.9%–99.6%). Median PFS was 6.1 months (95% CI, 0.5–8.1); median OS was not reached, with estimated 3- and 6-month OS rates of 100%.
CAR-T expansion was detected in all evaluable participants by flow cytometry and qPCR. Peak CAR+ T-cell levels ranged from 133 to 44,949 cells/mL, while CAR transgene copy numbers ranged from 1,357 to 8,063 copies/μg DNA. Higher CAR-T expansion was generally observed at higher dose levels. PD analyses demonstrated transient increases in inflammatory cytokines (including IL-6, IL-8, and IFN-γ) and dynamic CD4+/CD8+ T-cell changes. Notably, one participant received repeat CHT101 treatment courses exhibited reproducible CAR-T expansion and immune activation after each treatment course, providing preliminary evidence supporting the feasibility of a repeat-treatment strategy.
Exploratory biomarker analyses showed concordance between IHC and DIA-LC–MS/MS for CD70 expression status. DIA-LC–MS/MS showed concordance with IHC, detecting signals in IHC-positive but not IHC-negative samples. All responders were CD70-positive by IHC, and the CR participant showed the highest DIA-measured CD70 protein abundance. However, one CD70-positive participant with detectable protein expression experienced PD, suggesting that CD70 expression alone may not fully determine clinical response.
Conclusions
Preliminary results from the phase I COURAGE study demonstrate that CHT101, an allogeneic CD70-targeted CAR-T therapy, has a manageable safety profile, effective in vivo expansion, and promising early antitumor activity in participants with R/R hematologic malignancies. Exploratory biomarker analyses suggest a potential association between CD70 expression level and clinical response. Continued enrollment and follow-up are ongoing to further evaluate CHT101 in R/R hematologic malignancies.
DISCLOSURES
Jingwei Yu, MD: No relevant conflicts of interest to declare.